The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price raised by Scotiabank from $45.00 to $48.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a sector ...
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for BridgeBio Pharma in a report released ...
We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...
In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned an average recommendation of “Moderate ...
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback